Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 10;56(1):15-30.
doi: 10.1021/jm301448p. Epub 2012 Dec 17.

Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design

Anders Friberg  1 , Dominico Vigil, Bin Zhao, R Nathan Daniels, Jason P Burke, Pedro M Garcia-Barrantes, DeMarco Camper, Brian A Chauder, Taekyu Lee, Edward T Olejniczak, Stephen W Fesik
Affiliations

Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design

Anders Friberg et al. J Med Chem. .

Abstract

Myeloid cell leukemia 1 (Mcl-1), a member of the Bcl-2 family of proteins, is overexpressed and amplified in various cancers and promotes the aberrant survival of tumor cells that otherwise would undergo apoptosis. Here we describe the discovery of potent and selective Mcl-1 inhibitors using fragment-based methods and structure-based design. NMR-based screening of a large fragment library identified two chemically distinct hit series that bind to different sites on Mcl-1. Members of the two fragment classes were merged together to produce lead compounds that bind to Mcl-1 with a dissociation constant of <100 nM with selectivity for Mcl-1 over Bcl-xL and Bcl-2. Structures of merged compounds when complexed to Mcl-1 were obtained by X-ray crystallography and provide detailed information about the molecular recognition of small-molecule ligands binding Mcl-1. The compounds represent starting points for the discovery of clinically useful Mcl-1 inhibitors for the treatment of a wide variety of cancers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
1H-15N HMQC spectra of Mcl-1 with (red) and without (black) fragment 3. The NMR sample contained 50μM 15N-labeled protein and 800HM ligand.
Figure 2
Figure 2
Model structures of Mcl-1 complexed to two different classes of fragment hits obtained using NMR-derived distance restraints. Residues (labeled) with NOEs to the fragments (blue) are rendered as sticks (gray). R263 is also labeled. (A) Class I: benzothiophene 5, and (B) Class II: tethered aromatic 17.
Figure 3
Figure 3
Schematic illustrating the merging of fragment 2 and 17 to produce compound 60. The affinity of each molecule to Mcl-1 is shown as well as the ligand efficiencies.
Figure 4
Figure 4
X-ray structures of merged compounds bound to Mcl-1. Compounds incorporating different scaffolds (benzothiophene and indole) occupy the same binding pocket and adopt very similar binding poses (inset). (A) Compounds 53 and 60 interact with Mcl-1 in the BH3-peptide binding cleft between helices 3, 4, and 5. Surface depiction of Mcl-1 when complexed to (B) 60 and (C) 53 that illustrates how the merged compounds fill the pockets as predicted by NMR and interact with R263.
Figure 5
Figure 5
Several structural differences between peptide-bound (red) and compound-bound (gray) Mcl-1 complexes were identified. The Mcl-1-derived BH3-peptide is depicted in green and compound 60 in blue. (A) To accommodate the hydrophobic fragments into the deep pocket, helix 4 (α4) is slightly kinked in the structures of Mcl-1/compound complexes compared to the Mcl-1/peptide structures. This leads to further rearrangements of the loop, pulling it towards the merged compound. (B) Close-up of the small-molecule binding-site in Mcl-1. Compared to the peptide-bound state, our merged compounds induce changes in the position and/or in rotamer states of nearby residues. (C-D) The network of charge-charge interactions and polar contacts involving R263 are dramatically different in the two types of complexes. (C) While bound to the peptide, R263 of Mcl-1 interacts closely with D218 of the 16mer, a residue shown important by alanine-scanning. Moreover, R263 interacts with the side-chain of D256 and the backbone (bb) oxygen of V258 in Mcl-1. (D) When complexed with merged compounds (e.g. 60), this network is replaced by an interaction to the carboxylic acid of the small-molecule ligand and additional polar contacts to the backbone oxygen atoms of S255 and D256.
Figure 6
Figure 6
(A) Comparison of Mcl-1 (gray surface) when complexed to compound 60 (blue) and a 16mer BH3-peptide derived from Mcl-1 (green), (B) Overlay of the X-ray structures of Mcl-1/60 complex and Bcl-xL/ABT-737 (PDB: 2YXJ). The Mcl-1 protein is shown in gray, 60 in blue, and ABT-737 in green.
Scheme 1
Scheme 1
Synthesis of benzothiophene- and benzofuran-containing compounds
Scheme 2
Scheme 2
Synthesis of indole-based compounds
Scheme 3
Scheme 3
Synthesis of compounds 69-72
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205–219. - PubMed
    1. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324–1337. - PMC - PubMed
    1. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, Strasser A, Kluck RM, Adams JM, Huang DCS. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science. 2007;315:856–859. - PubMed
    1. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho Y-J, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao M-S, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899–905. - PMC - PubMed
    1. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, Shehata S, Kung AL, Beroukhim R, Golub TR. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 2012;21:547–562. - PMC - PubMed

Publication types

MeSH terms